glp 1 drug shortage FDA's compounded GLP-1 limits will have ripple effects throughout the retail industry GLP-1 Drugs: The Science and

Starting without a documented baseline creates two significant problems

This article profiles these trials and their implications for management of CVD in people with obesity after briefly tracing the path to the launch of these studies

A post hoc analysis of the phase IIb trial showed that tirzepatide was associated with a reduction in the level of high-sensitivity ICAM-1, CRP, and YKL-40 after 26 weeks of treatment in a dose-dependent manner [83, 103]

India leads in the number of generics that were announced in the wake of this patent expiry

Biosimilars Under the Medical Benefit 6.5

That will not be the case in 2026